Prostaglandin (PG) analogs, including latanoprost, travoprost, and bimatoprost, are currently the most commonly used topical ocular hypotensive medications. The purpose of this study was to investigate the corneal alterations in rabbits following exposure to commercial solution of latanoprost, travoprost and bimatoprost. A total of 64 New Zealand albino rabbits were used and four groups of treatments were constituted. Commercial latanoprost, travoprost, bimatoprost or 0.02% benzalkonium chloride (BAK) was applied once daily to one eye each of rabbits for 30 days. The contralateral untreated eyes used as controls. Schirmer test, tear break-up time (BUT), rose Bengal and fluorescein staining were performed on days 5, 10, 20, and 30. Central corneal changes were analyzed by in vivo confocal microscopy, and the corneal barrier function was evaluated by measurement of corneal transepithelial electrical resistance on day 5. Whole mount corneas were analyzed by using fluorescence confocal microscopy for the presence of tight-junction (ZO-1, occludin) and adherens-junction (E-cadherin, β-catenin) proteins, actin cytoskeleton, proliferative marker Ki67 and cell apoptosis in the epithelium. Topical application of commercial PG analogs resulted in significant corneal epithelial and stromal defects while no significant changes in aqueous tear production, BUT, rose bengal and fluorescein staining scores on day 5. Commercial PG analogs induced dislocation of ZO-1 and occludin from their normal locus, disorganization of cortical actin cytoskeleton at the superficial layer, and disruption of epithelial barrier function. The eyes treated with 0.02% BAK and latanoprost exhibited significantly reduced Schirmer scores, BUT, and increased fluorescein staining scores on days 10 and 30, respectively. Topical application of commercial PG analogs can quickly impair the corneal epithelium and stroma without tear deficiency. Commercial PG analogs break down the barrier integrity of corneal epithelium, concomitant with the disruption of cell junction and actin cytoskeleton between superficial cells in the corneal epithelium in vivo.
References
[1]
Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. Journal of pharmaceutical science 87: 1479–1488. doi: 10.1021/js9802594
[2]
Kinoshita S, Adachi W, Sotozono C, Nishida K, Yokoi N, et al. (2001) Characteristics of human ocular surface epithelium. Prog Retin Eye Res 20: 639–673. doi: 10.1016/s1350-9462(01)00007-6
[3]
Kalinin AE, Kajava AV, Steinert PM (2002) Epithelial barrier function: assembly and structural features of the cornified cell envelope Bioessays. 24: 789–800. doi: 10.1002/bies.10144
[4]
Crone C, Olesen SP (1982) Electrical resistance of brain microvascular enthelium. Brain Res 241: 49–55. doi: 10.1016/0006-8993(82)91227-6
[5]
Vandenbrouche E, Methta D, Minshall R, Malik AB (2008) Regulation of endothelial junctional permeability. Ann N Acad Sci 1123: 134–145. doi: 10.1196/annals.1420.016
[6]
Miyoshi J, Takai Y (2008) Structural and functional associations of apical junction with cytoskeleton. Biochim Biophys Acta 1778: 670–691. doi: 10.1016/j.bbamem.2007.12.014
[7]
Cereijido M, Contreras RG, Shoshani L, Flores-Benitez D, Larre I (2008) Tight junction and polarity interaction in the transporting epithelial phenotype. Biochim Biophys Acta 1778: 770–793. doi: 10.1016/j.bbamem.2007.09.001
[8]
Kimura K, Morita Y, Orita T, Haruta J, Takeji Y, et al. (2013) Protection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipide. Invest Ophthalmol Vis Sci 54: 2572–2570. doi: 10.1167/iovs.12-11294
[9]
McKee HD, Gupta MS, Ahad MA, Salda？a M, Innes JR (2005) First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye 19: 923–924. doi: 10.1038/sj.eye.6701674
[10]
Cracknell KP, Grierson I (2009) Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Exp Eye Res 88: 786–791. doi: 10.1016/j.exer.2008.08.022
[11]
Parrish RK, Palmberg P, Sheu W-P (2003) A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135: 688–703. doi: 10.1016/s0002-9394(03)00098-9
[12]
Crichton ACS, Vold Steven, Williams JM Hollander DA (2013) Ocular surface tolerability in patients with glaucoma or ocular hypertension. Adv Ther 30: 260–270. doi: 10.1007/s12325-013-0014-7
[13]
Pauly A, Roubeix C, Liang H, Brignole-Baudouim F, Baudouin C (2012) In vitro and in vivo comparative toxicological study of new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci 53: 8172–8180. doi: 10.1167/iovs.12-10766
[14]
Nakagawa S, Usui T, Yokoo S, Omichi S, Kimakura M, et al. (2012) Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets. Invest Ophthalmol Vis Sci 53: 5154–8180. doi: 10.1167/iovs.12-9685
[15]
Chen W, Li Z, Hu J, Zhang Z, Chen L, et al. (2011) Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLoS ONE 6(10): e26103. doi: 10.1371/journal.pone.0026103
[16]
Chen W, Hu J, Zhang Z, Chen L, Xie H, et al. (2012) Localization and expression of zonula occludins-1 in the rabbit corneal epithelium following exposure to benzalkonium chloride. PLoS ONE 7(7): e40893. doi: 10.1371/journal.pone.0040893
[17]
Kusano M, Uematus M, Kumagami T, Sasaki H, Kitaoka T (2010) Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea 29: 80–85. doi: 10.1097/ico.0b013e3181a3c3e6
[18]
Guenoun J-M, Baudouin C, Rat P, Pauly A, Warnet J-M, et al. (2005) In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derives epithelial cells. Invest Ophthalmol Vis Sci 46: 2444–2450. doi: 10.1167/iovs.04-1331
[19]
Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, et al. (2004) Conjunctival proinflammatory and proapototic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 45: 1360–1368. doi: 10.1167/iovs.03-1067
[20]
Guenoun J-M, B audouin C, Rat P, Pauly A, Warnet J-M, et al. (2005) In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 46: 4594–4599. doi: 10.1167/iovs.05-0776
[21]
Yanai R, Ko J-A, Morishige N, Chiakama T, Ichijima H, et al. (2009) Disruption of zonula occludens-1 localization in the rabbit corneal epithelium by contact lens-induced hypoxia. Invest Ophthalmol Vis Sci 50: 4605–4610. doi: 10.1167/iovs.09-3407
[22]
Guo Ying, Satpahy M, Wilson G, Srinivas SP (2007) Benzalkonium chloride induces dephosphorylation of myosin light chain in cultured corneal epithelial cells. Invest Ophthalmol Vis Sci 48: 2001–2008. doi: 10.1167/iovs.06-0613
[23]
Chinnery HR, Pearlman E, McMenamin PG (2008) Cutting edge: Membrane nanotubes in vivo: a feature of MHC class II+ cells in the mouse cornea. 180: 5779–5783. doi: 10.4049/jimmunol.180.9.5779
[24]
Liang H, Pauly A, Riancho L, Baudouin C, Brignole-Baudouin F (2011) Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol 95: 869–875. doi: 10.1136/bjo.2010.189449
[25]
Georgiev GA, Norihiko Y, Koev K, Kutsarova E, Ivanova S, et al. (2011) Surface chemistry study of the interactions of benzalkonium chloride with films of meibum, corneal lipids, and whole tears. Invest Ophthalmol Vis Sci 52: 4645–4654. doi: 10.1167/iovs.10-6271
[26]
Yu F, Liu X, Zhong Y, Guo X, Li M, et al. (2013) Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprot: an in vivo study. Invest Ophthalmol Vis Sci 54: 3385–3393. doi: 10.1167/iovs.12-11181
[27]
Chen W, Zhang Z, Hu J, Xie H, Pan J, et al. (2013) Changes in corneal innervation induced by the topical application of benzalkonium chloride. Cornea 32: 1599–1606. doi: 10.1097/ico.0b013e3182a8196f
